1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. Financials
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
Real-time Euronext Bruxelles  -  11:23 2022-07-05 am EDT
1.830 EUR   -1.19%
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tagrisso
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 511323268208107-
Enterprise Value (EV)1 482310294309258285
P/E ratio -10,6x-5,02x-4,19x-2,87x-1,97x-2,85x
Yield ------
Capitalization / Revenue 17,8x8,55x4,82x3,79x1,67x1,21x
EV / Revenue 16,8x8,23x5,30x5,62x4,04x3,22x
EV / EBITDA -11,3x-6,76x-7,93x-5,85x-6,08x-11,7x
Price to Book 5,84x-----
Nbr of stocks (in thousands) 51 36156 38257 54657 54657 546-
Reference price (EUR) 9,945,724,653,621,851,85
Announcement Date 02/28/201903/05/202002/25/202102/24/2022--
1 EUR in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 28,737,755,654,963,888,3
EBITDA1 -42,6-45,9-37,1-52,8-42,4-24,3
Operating profit (EBIT)1 -46,9-55,6-46,9-62,6-48,0-32,0
Operating Margin -164%-147%-84,3%-114%-75,3%-36,3%
Pre-Tax Profit (EBT)1 -48,3--63,2-71,7-56,0-40,0
Net income1 -48,2-64,1-62,9-71,5-53,0-37,0
Net margin -168%-170%-113%-130%-83,1%-41,9%
EPS2 -0,94-1,14-1,11-1,26-0,94-0,65
Dividend per Share ------
Announcement Date 02/28/201903/05/202002/25/202102/24/2022--
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2018 S1 2019 S1
Net sales1 12,717,3
EBITDA --
Operating profit (EBIT)1 -21,1-26,7
Operating Margin -166%-154%
Pre-Tax Profit (EBT) -21,8-
Net income -21,8-
Net margin -171%-
EPS -0,42-
Dividend per Share --
Announcement Date 09/06/201809/05/2019
1 EUR in Million
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 --26,9101151178
Net Cash position1 28,212,1----
Leverage (Debt / EBITDA) 0,66x0,26x-0,72x-1,91x-3,57x-7,33x
Free Cash Flow1 -47,8-56,8-42,3-69,4-49,0-27,0
ROE (Net Profit / Equities) -43,9%-74,6%----
Shareholders' equity1 11085,9----
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share 1,70-----
Cash Flow per Share -0,82-0,97-0,69---
Capex1 5,832,523,023,696,006,00
Capex / Sales 20,3%6,67%5,44%6,71%9,41%6,80%
Announcement Date 02/28/201903/05/202002/25/202102/24/2022--
1 EUR in Million
Previous periodNext period
Estimates
Key data
Capitalization (EUR) 106 574 567
Capitalization (USD) 111 142 525
Net sales (EUR) 54 898 000
Net sales (USD) 57 251 017
Number of employees 619
Sales / Employee (EUR) 88 688
Sales / Employee (USD) 92 490
Free-Float 86,4%
Free-Float capitalization (EUR) 92 053 961
Free-Float capitalization (USD) 95 999 542
Avg. Exchange 20 sessions (EUR) 127 873
Avg. Exchange 20 sessions (USD) 133 354
Average Daily Capital Traded 0,12%
EPS & Dividend